Economic value of gonorrhea resistance testing in the United States: A multi-perspective modeling study
by Brooke E. Nichols, Betsy Wonderly Trainor, Grace Hampson, Yonatan H. Grad, Jeffrey D. Klausner Background Rising antimicrobial resistance in Neisseria gonorrhoeae threatens the effectiveness of existing therapies. Ceftriaxone is the only recommended first-line (empiric) treatment for uncomplicated gonorrhea in the United States. Ciprofloxacin is no longer recommended for empiric use because of…
We haven't written up this one. PLOS Medicine has the full story — the link below goes straight to it.